Li Shoujun, chairman of the board of directors, received a warning letter

According to the decision on administrative supervision measures of Dalian regulatory bureau of China Securities Regulatory Commission (jzjg [2020] No.27, No.28 and No.29) recently released on the website of China Securities Regulatory Commission, Tianjin Ruipu Biotechnology Co., Ltd. (hereinafter referred to as “Ruipu biotechnology”, 300119. SZ) has the following violations: < / P > < p > the company’s marketing center is opened in the name of employees Set up an account to collect customers’ money, and the “risk margin” money is not included in the company’s account storage and accounting. The “risk margin” of the company’s customers not included in the account storage and accounting in 2019 and 2020 are 30.9376 million yuan and 12.4555 million yuan respectively, which affects the accuracy of the data of assets and liabilities in the company’s annual report in 2019 and interim report in 2020, as well as the accuracy of the company’s internal control self-evaluation report in 2019. The above behavior violates the provisions of the first paragraph of Article 2 of the measures for the administration of information disclosure of listed companies. According to Article 59 of the administrative measures for information disclosure of listed companies, Tianjin Securities Regulatory Bureau decided to issue a warning letter to Ruipu biological. Rip bio should take effective measures to strengthen internal control and ensure the quality of information disclosure. < p > < p > during the occurrence of the above violations, Li Shoujun served as the chairman and general manager of Ruipu biology, and made a statement and signed as the person in charge of accounting work in the annual report of 2019 and the interim report of 2020. Li Shoujun failed to faithfully and diligently perform his duties and was responsible for the above-mentioned violations of the company, in violation of Article 3 of the administrative measures for information disclosure of listed companies. According to the provisions of Article 58 and Article 59 of the administrative measures for information disclosure of listed companies, Tianjin Securities Regulatory Bureau decided to issue a warning letter to Li Shoujun. Li Shoujun should strengthen the study of laws and regulations, faithfully and diligently perform his duties, and put an end to the recurrence of such violations. < / P > < p > during the occurrence of the above violations, Xu Lei served as the person in charge of Ruipu biological marketing center, deputy general manager of the company on December 25, 2019, and director of the company on April 23, 2020. Xu Lei failed to faithfully and diligently perform his duties, and was responsible for the above-mentioned violations of the company, in violation of Article 3 of the administrative measures for information disclosure of listed companies. According to the provisions of Article 58 and Article 59 of the measures for the administration of information disclosure of listed companies, Tianjin Securities Regulatory Bureau decided to issue a warning letter to Xu Lei. Xu Lei should strengthen the study of laws and regulations, faithfully and diligently perform his duties, and prevent the recurrence of such violations. < / P > < p > according to ripple bio’s website, ripple bio was founded in 1998. It has six GMP production bases, including Ruipu (Tianjin) biopharmaceutical Co., Ltd., Ruipu (Baoding) biopharmaceutical Co., Ltd., Tianjin Ruipu Biotechnology Co., Ltd. high tech branch, Hubei Longxiang Pharmaceutical Co., Ltd., Hunan Zhongan biopharmaceutical Co., Ltd. and Inner Mongolia Ruipu Dadi Animal Pharmaceutical Co., Ltd., with API production line, powder / powder / premix and oral liquid Since then, he has been the chairman, general manager and director of Ruipu biology. Li Shoujun, the largest shareholder and actual controller, holds 41.40% of the shares of rip bio. < p > < p > Xu Lei has been a technician and regional manager of Ruipu Tianjin since 2000. He has been the marketing director of Ruipu Tianjin, the general manager of Hunan Zhongan, the general manager and supervisor of the company’s marketing center for more than 10 years. He has been the deputy general manager since December 25, 2019 and the director of the company since April 23, 2020. < p > < p > Article 2 of the administrative measures for information disclosure of listed companies stipulates that the information disclosure obligors shall truly, accurately, completely and timely disclose the information, and there shall be no false records, misleading statements or major omissions. < / P > < p > the information disclosed in the overseas market by a company that issues securities and their derivatives and is listed in the domestic and overseas markets shall be disclosed in the domestic market at the same time. Article 3 of the administrative measures for information disclosure of listed companies stipulates that issuers, directors, supervisors and senior managers of listed companies shall faithfully and diligently perform their duties to ensure the authenticity, accuracy, integrity, timeliness and fairness of the information disclosed. < p > < p > Article 58 of the administrative measures for information disclosure of listed companies stipulates that the directors, supervisors and senior managers of listed companies shall be responsible for the authenticity, accuracy, integrity, timeliness and fairness of the company’s information disclosure, unless there is sufficient evidence to show that they have performed their duty of diligence. < p > < p > the chairman, manager and Secretary of the board of directors of a listed company shall bear the main responsibility for the authenticity, accuracy, integrity, timeliness and fairness of the information disclosure of the company’s interim report. < / P > < p > the chairman, manager and financial principal of a listed company shall be mainly responsible for the authenticity, accuracy, integrity, timeliness and fairness of the company’s financial report. Article 59 of the measures for the administration of information disclosure of listed companies stipulates that if the information disclosure obligors and their directors, supervisors and senior managers, as well as the shareholders, actual controllers and purchasers of listed companies and their directors, supervisors and senior managers violate the measures, the CSRC may take the following regulatory measures: < / P > < p > the company’s marketing center shall focus on employees An account is opened in the name of an individual to collect money from customers, and the “risk margin” money is not included in the company’s account storage and accounting. The “risk margin” of the company’s customers not included in the account storage and accounting in 2019 and 2020 are 30.9376 million yuan and 12.4555 million yuan respectively, which affects the accuracy of the data of assets and liabilities in the company’s annual report in 2019 and interim report in 2020, as well as the accuracy of the company’s internal control self-evaluation report in 2019. The above behavior violates the provisions of the first paragraph of Article 2 of the measures for the administration of information disclosure of listed companies. < / P > < p > according to Article 59 of the measures for the administration of information disclosure of listed companies, our bureau has decided to issue a warning letter to your company for administrative supervision. Your company should take effective measures to strengthen internal control and ensure the quality of information disclosure. < / P > < p > if you are not satisfied with the supervision and management measures, you can apply for administrative reconsideration to China Securities Regulatory Commission within 60 days from the date of receiving this decision, or file a lawsuit to the people’s court with jurisdiction within 6 months from the date of receiving this decision. During the period of reconsideration and litigation, the above supervision and management measures shall not be suspended. < / P > < p > the company’s marketing center opened an account in the name of employees to collect customers’ money, and the “risk margin” money was not included in the company’s account storage and accounting. The “risk margin” of the company’s customers not included in the account storage and accounting in 2019 and 2020 are 30.9376 million yuan and 12.4555 million yuan respectively, which affects the accuracy of the data of assets and liabilities in the company’s annual report in 2019 and interim report in 2020, as well as the accuracy of the company’s internal control self-evaluation report in 2019. The above behavior violates the provisions of the first paragraph of Article 2 of the measures for the administration of information disclosure of listed companies. < / P > < p > during the occurrence of the above-mentioned violations, you are the chairman and general manager of Ruipu biology, and in the annual report of 2019 and the interim report of 2020, you declare and sign as the person in charge of accounting work. If you fail to perform your duties faithfully and diligently, you are responsible for the above-mentioned violations of the company, which violates Article 3 of the administrative measures for information disclosure of listed companies. < / P > < p > according to the provisions of Article 58 and Article 59 of the measures for the administration of information disclosure of listed companies, our bureau has decided to take administrative supervision measures to issue a warning letter to you. You should strengthen the study of laws and regulations, faithfully and diligently perform your duties, and prevent the recurrence of such violations. < / P > < p > if you are not satisfied with the supervision and management measures, you can apply for administrative reconsideration to China Securities Regulatory Commission within 60 days from the date of receiving this decision, or file a lawsuit to the people’s court with jurisdiction within 6 months from the date of receiving this decision. During the period of reconsideration and litigation, the above supervision and management measures shall not be suspended. < / P > < p > the company’s marketing center opened an account in the name of employees to collect customers’ money, and the “risk margin” money was not included in the company’s account storage and accounting. The “risk margin” of the company’s customers not included in the account storage and accounting in 2019 and 2020 are 30.9376 million yuan and 12.4555 million yuan respectively, which affects the accuracy of the data of assets and liabilities in the company’s annual report in 2019 and interim report in 2020, as well as the accuracy of the company’s internal control self-evaluation report in 2019. The above behavior violates the provisions of the first paragraph of Article 2 of the measures for the administration of information disclosure of listed companies. < / P > < p > during the occurrence of the above violations, you will be the person in charge of rip biological marketing center, the deputy general manager of the company on December 25, 2019, and the director of the company on April 23, 2020. If you fail to perform your duties faithfully and diligently, you are responsible for the above-mentioned violations of the company, which violates Article 3 of the administrative measures for information disclosure of listed companies. < / P > < p > according to the provisions of Article 58 and Article 59 of the measures for the administration of information disclosure of listed companies, our bureau has decided to take administrative supervision measures to issue a warning letter to you. You should strengthen the study of laws and regulations, faithfully and diligently perform your duties, and prevent the recurrence of such violations. < / P > < p > if you are not satisfied with the supervision and management measures, you can apply for administrative reconsideration to China Securities Regulatory Commission within 60 days from the date of receiving this decision, or file a lawsuit to the people’s court with jurisdiction within 6 months from the date of receiving this decision. During the period of reconsideration and litigation, the above supervision and management measures shall not be suspended. < p > < p > the purpose of this article is to convey more information, and it does not represent the views and positions of our website. The content of this article is for reference only, and does not constitute an investment proposal. Investors operate on this basis at their own risk.